Evidence map›Paper›PMID 31456494›Full record

ArticleJournal of managed care & specialty pharmacy2019

Letter--Assessing the Effectiveness of V-BID Implementations.

Beth Shrosbree, A Mark Fendrick

Abstract readLetter
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Beth ShrosbreeCenter for Value-Based Insurance Design University of Michigan, Ann Arbor shrosbet@umich.edu.
A Mark FendrickCenter for Value-Based Insurance Design University of Michigan, Ann Arbor amfen@umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

disclosuresNo outside funding supported the writing of this letter. Fendrick discloses consulting relationships with AbbVie, Amgen, Centivo, Community Oncology Association, Department of Defense, EmblemHealth, Exact Sciences, Freedman Health, Health at Scale Technologies, Health Management Associates, Lilly, MedZed, Penguin Pay, Risalto, Sempre Health, State of Minnesota, Wellth, and Zansors and also discloses a research relationship with AHRQ, Boehringer-Ingelheim, Gary and Mary West Health Policy Center, Laura & John Arnold Foundation, National Pharmaceutical Council, PCORI, PhRMA, RWJ Foundation, and State of Michigan/CMS. Shrosbree has nothing to disclose.

Indexed as

Cost-Benefit AnalysisDelivery of Health CareHealth Care CostsHumansInsuranceMichiganMinnesotaPrescription DrugsPrescription Drugs

Identifiers

PMID31456494
PMCPMC10397857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.